First human test of potential Parkinson's-Blocking drug begins
NCT ID NCT07216066
Summary
This is the first study in people to test an experimental drug called ALN-SNCA for early Parkinson's disease. The main goal is to check if the drug is safe and well-tolerated when given as a single injection into the spinal fluid. Researchers will also measure if the drug can lower levels of a harmful brain protein linked to Parkinson's and see how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Human Drug Research
RECRUITINGLeiden, South Holland, 2333 CL, Netherlands
Conditions
Explore the condition pages connected to this study.